9 hidden AI stocks set to thrive in Trump’s new era

AI ETFs are Booming, But These 9 AI Stocks are Better Plays By 2030, the AI industry is projected to be worth trillions of dollars (here’s how to tap into this new wealth)

Daniel Florin Biography and Net Worth

Director of Pulmonx

Daniel P. Florin has served as a member our board of directors since January 2020. From July 2019 to March 2020, Mr. Florin served as Executive Vice President of Zimmer Biomet Holdings Inc., a medical device company. From June 2015 to July 2019, Mr. Florin served as Zimmer Biomet’s Executive Vice President and Chief Financial Officer. From July 2017 to December 2017, Mr. Florin served as Zimmer Biomet’s Interim Chief Executive Officer. From June 2007 to June 2015, Mr. Florin served as Senior Vice President and Chief Financial Officer at Biomet, Inc. (prior to Biomet’s merger with Zimmer). From January 2001 to May 2007, Mr. Florin served as Vice President and Corporate Controller of Boston Scientific Corporation. Mr. Florin has served as a board member at AtriCure, Inc. (NASDAQ: ATRC) since December 2019. Mr. Florin holds a B.A. with a concentration in Accounting from the University of Notre Dame and an M.B.A. from Boston University. We believe that Mr. Florin is qualified to serve as a member of our board of directors because of his extensive experience in the medical device industry.

What is Daniel P. Florin's net worth?: The estimated net worth of Daniel P. Florin is at least $34,167.28 as of June 25th, 2021. Mr. Florin owns 5,032 shares of Pulmonx stock worth more than $34,167 as of November 24th. This net worth approximation does not reflect any other investments that Mr. Florin may own. Learn More about Daniel P. Florin's net worth.
How do I contact Daniel P. Florin?: The corporate mailing address for Mr. Florin and other Pulmonx executives is , , . Pulmonx can also be reached via phone at 1-650-364-0400 and via email at [email protected]. Learn More on Daniel P. Florin's contact information.
Has Daniel P. Florin been buying or selling shares of Pulmonx?: Daniel P. Florin has not been actively trading shares of Pulmonx over the course of the past ninety days. Most recently, on Monday, July 12th, Daniel P. Florin bought 2,500 shares of Pulmonx stock. The stock was acquired at an average cost of $40.00 per share, with a total value of $100,000.00. Learn More on Daniel P. Florin's trading history.
Who are Pulmonx's active insiders?: Pulmonx's insider roster includes Daniel Florin (Director), Glendon French, III (CEO), David Lehman (General Counsel), Geoffrey Rose (Insider), and Derrick Sung (CFO). Learn More on Pulmonx's active insiders.
Are insiders buying or selling shares of Pulmonx?: In the last twelve months, Pulmonx insiders bought shares 1 times. They purchased a total of 14,245 shares worth more than $97,435.80. In the last twelve months, insiders at the sold shares 24 times. They sold a total of 138,186 shares worth more than $1,346,575.19. The most recent insider tranaction occured on October, 17th when Director Glendon E French III sold 20,000 shares worth more than $130,400.00. Insiders at Pulmonx own 5.7% of the company. Learn More about insider trades at Pulmonx.
Information on this page was last updated on 10/17/2024.

Daniel P. Florin Insider Trading History at Pulmonx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/12/2021	Buy	2,500	$40.00	$100,000.00
6/25/2021	Buy	2,222	$44.12	$98,034.64	5,032

Daniel P. Florin Buying and Selling Activity at Pulmonx

Pulmonx Company Overview

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Today's Range

Now: $6.79

$6.25

$6.84

50 Day Range

MA: $7.07

$6.00

$8.58

2 Week Range

Now: $6.79

$5.46

$14.84

Volume

294,058 shs

Average Volume

233,713 shs

Market Capitalization

$268.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

9 hidden AI stocks set to thrive in Trump’s new era

From StockEarnings | Ad